Depomed gains rights to Zipsor from Xanodyne
Depomed acquired the product in return for potential milestone payments based on the sales of Zipsor and assumption of certain liabilities. Depomed president and CEO Jim Schoeneck said
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
Daikyo Seiko, West’s partner, developed these technologies, which are based on a polymeric container, utilizing elastomeric components with Flurotec barrier film, and provided in a sterile, validated, ready-to-fill